Boehringer Ingelheim Gmbh

Dr. Karl Thomae Gmbh

Basf Aktiengesellschaft

Other

Peter Gruber

Rolf Stefan Brickl

Gerhard Bozler

Gottfried Schepky

Herbert Stricker

Gunther Voss

Dietrich Arndts

Bernhard Freund

Wolf D Bechtel

Jochen Schmid

Siegfried Darda

Karl L Rominger

Heribert Harwalik

Volkmar Haselbarth

Rudolf Hurnaus

Wolfgang Steglich

Gunther M Voss

Volker I Glasel

Ursula Springmeier

Walter Bubeck

Boerries Kuebel

Wolfgang Eisert

Eckhart Bauer

Willy Roth

Ulrich Busch

Horst Lechner

Alain Etienne

The specification describes a pharmaceutical combination consisting of dipyridamole or mopidamol and acetylsalicylic acid or the physiologically acceptable salts thereof, processes for preparing this pharmaceutical combination and the use thereof for the controlled prevention of clot formation.

Pharmaceutical compositions containing dipyridamole or mopidamol and

Pharmaceutical forms of pimobendan for oral administration comprising citric acid, whereby a constant, satisfactory resorption is ensured even when there are major pH fluctuations in the gastrointestinal tract.

Oral pharmaceutical forms of pimobendan

The invention is directed to a process and apparatus for dotting molding tools with droplets of liquid or suspended lubricant in the production of shaped articles in the pharmaceutical, food, or catalyst fields. Pressurized lubricant solutions or suspensions and pressurized gas are alternately passed through capillaries, in conjunction with alternating single-substance nozzles, in such a way that drops are formed on the nozzle surface, in between the jets of gas, and are then detached from this surface and directed to specific zones of pressing tools. The apparatus comprises fast-acting valves for the brief release of pressurized gases and lubricant liquids or suspensions. The delivery lines of a gas valve and a liquid valve combine upstream of a capillary, and single-substance nozzles are mounted at the end of the capillaries.

Dotting of molding tools with droplets

There is described a solid pharmaceutical preparation for oral administration which produces high and long-lasting blood and tissue levels, containing 9-deoxo-11-deoxy-9,11-[imino[2-(2-methoxyethoxy)-ethylidene]oxy]-(9S)-eryt hromycin as active substance, in which the active substance must be intimately mixed with a basic excipient in a ratio of 1 mol of active substance to at least 2 gram-equivalents of basic excipient, and the preparations are coated with a gastric juice-resistant lacquer which is soluble in a pH range of between 5.5 and 6.8, and processes for preparing them. The solid pharmaceutical preparations include tablets, pellets or granules and a syrup can be produced from the latter.

Oral pharmaceutical preparations containing

The invention is directed to a process for dotting molding tools with droplets of liquid or suspended lubricant in the production of shaped articles in the pharmaceutical, food, or catalyst fields. Pressurized lubricant solutions or suspensions and pressurized gas are alternately passed through capillaries, in conjunction with alternating single-substance nozzles, in such a way that drops are formed on the nozzle surface, in between the jets of gas, and are then detached form this surface and directed to specific zones of pressing tools. The apparatus comprises fast-acting valves for the brief release of pressurized gases and lubricant liquids or suspensions. The delivery lines of a gas valve and a liquid valve combine upstream of a capillary, and single-substance nozzles are mounted at the end of the capillaries.

This invention relates to vehicles for the administration of mopidamol. More specifically, this invention relates to a method of treating cardiovascular disorders, malignancy, or thrombosis in a host in need of such treatment which comprises administering to said host a cardiovascularly, antimetastic, or antithrombotic effective amount of a composition comprised of (i) mopidamol or an acid addition salt thereof and (ii) at least one pharmacologically acceptable acid or acid substance, the total amount of acid from acid addition salt present and acid or acid substance being in a ratio of at least about 1 acid equivalent to 1 mol of mopidamol or its acid addition salt.

Oral mopidamol preparation

This invention relates to vehicles for the administration of mopidamol. More specifically, this invention relates to a method of treating cardiovascular disorders, malignancy, or thrombosis in a host in need of such treatment which comprises administering to said host a cardiovascularly, antimetastic, or antithrombotic effective amount of a composition comprised of (i) mopidamol or an acid addition salt thereof and (ii) at least one pharmacologically acceptable acid or acid substance, the total amount of acid from acid addition salt present and acid or acid substance being in a ratio of at least about 1 acid equivalent to 1 mol of mopidamol.

This invention relates to a pharmaceutical dosage unit composition consisting essentially of a gelatin capsule containing (1) a disintegrating core comprising clonidine, said disintegrating core having a readily water-soluble coating, and (2) a plurality of non-disintegrating cores comprising clonidine, said non-disintegrating cores having a coating consisting of from 20 to 90 percent by weight of a water-insoluble film former and from 10 to 80 percent by weight of a water-soluble polymer, the diameter of each of the disintegrating and non-disintegrating cores being at least about 5 mm.

Retard form of pharmaceuticals with insoluble porous diffusion coatings

This invention is directed to a method for the non-contact application of letters or symbols to the exterior surfaces of uncoated tablets or uncoated tablet cores, which comprises dotting color solution or suspension by means of an ink-jet printer in specific quantity in the form of discrete droplets of specific volume onto the exterior surfaces of the uncoated tablets or uncoated tablet cores.

Method for ink-jet printing on uncoated tablets or uncoated tablet cores

A pharmaceutical dosage unit retard form having a constant, pH-independent release rate of active ingredient, consisting of a core comprising an active ingredient, and a semi-permeable diffusion coating over the core, where the coating consists of a water-insoluble film-former, a water-soluble polymer and eventually an acid-insoluble polymer incorporated therein.

This invention relates to vehicles for the administration of bromhexine. More specifically, this invention relates to a composition for the delayed release of bromhexine which comprises (i) spheroid particles or tablets comprised of (a) bromhexine and/or acid addition salts thereof and (b) at least one pharmacologically acceptable acid or acidic substance, the total amount of acid substance from acid addition salts present and the acid or acidic substance being in a ratio of at least 2 mols to 1 mol of bromhexine, and (ii) a coating surrounding said spheroid particles or tablets, said coating being comprised of from about 50 to 100 percent by weight of acid-insoluble lacquers soluble in intestinal juices and from about 0 to 50 percent by weight of lacquers insoluble in gastric and intestinal juices and said coating being present in an amount of from about 2 to 30 percent by weight, based upon the weight of the spheroid particles or tablets.

Bromhexine delayed-release pharmaceutical form

This invention relates to vehicles for the administration of dipyridamole. More specifically, this invention relates to a method of treating cardiovascular disorders in a host in need of such treatment which comprises administering to said host a cardiovascularly effective amount of a composition comprised of (i) dipyridamole or an acid addition salt thereof and (ii) at least one pharmacologically acceptable acid or acid substance, the total amount of acid from acid addition salt present and acid or acid substance being in a ratio of at least about 5 acid equivalents to 1 mol of dipyridamole, preferably in the form of particles having particle sizes of from about 0.1 to 2.0 mm.

Dipyridamole-containing pharmaceutical form

A method and apparatus for the coating of molding tools which comprises dispersing liquid or suspended lubricant in directional manner before each pressing operation in discrete, specific droplets onto the pressing zones of the molding tools, said dispersing being effected by means of f.i. piezoelectric transducers.

Method and apparatus for lubricating molding tools

This invention relates to a composition for the sustained release of dipyridamole which comprises (i) spheroid particles comprised of dipyridamole or crystallized salts thereof and pharmacologically acceptable acid or acid substance, and (ii) a coating surrounding said spheroid particles, said coating being comprised of from about 50 to 100 percent by weight of acid-insoluble lacquers soluble in intestinal juices and from about 0 to 50 percent by weight of lacquers insoluble in gastric and intestinal juices and said coating being present in an amount of from about 3 to 30 percent by weight, based on the weight of the spheroid particles, and to the preparation of such a composition.

Dipyricamole sustained release forms comprising lacquer-coated particles

A pharmaceutical dosage unit retard form having a constant, pH-independent release rate of active ingredient, consisting of a core comprising an active ingredient, and a semi-permeable diffusion coating over the core, were the coating consists of a water-insoluble film-former, a water-soluble polymer and eventually an acid-insoluble polymer incorporated therein.

Growing community of inventors

Biberach, Germany

Peter Gruber